Statistics for Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis
Total visits
| views | |
|---|---|
| Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis | 4 |
Total visits per month
| views | |
|---|---|
| January 2024 | 0 |
| February 2024 | 0 |
| March 2024 | 0 |
| April 2024 | 3 |
| May 2024 | 0 |
| June 2024 | 1 |
| July 2024 | 0 |
File Visits
| views | |
|---|---|
| Nikolaou2021Belantamab-CCBYNCND.pdf | 4 |
Top country views
| views | |
|---|---|
| United States | 3 |
| India | 1 |
Top city views
| views | |
|---|---|
| Bloomington | 2 |
| Columbus | 1 |
| Pune | 1 |